Mounjaro KwikPen 15 mg
Mounjaro KwikPen 15 mg
Mounjaro KwikPen 15 mg – Product Information, Uses, Dosage and Price in Ireland
1. Product Overview
Product name: Mounjaro KwikPen 15 mg
Active ingredient: Tirzepatide
Brand owner: Eli Lilly
Dosage form: Solution for injection
Delivery system: Multi-dose, pre-filled injection pen
Strength: 15 mg per dose
Administration: Subcutaneous injection (under the skin)
Dosing frequency: Once weekly, as prescbvribed
Pack contents: One pre-filled pen containing four fixed weekly doses
Prescription status in Ireland: Prescription-only medicine.
HPRA +1
Mounjaro contains tirzepatide, a medicine that acts on GIP and GLP-1 receptors. It is used for the treatment of type 2 diabetes and, in eligible patients, weight management alongside dietary changes and physical activity. Whether it is appropriate for an individual depends on their medical history and a healthcare professional's assessment.
2. What Is Mounjaro KwikPen 15 mg?
Mounjaro KwikPen 15 mg is a prescription medicine supplied in a pre-filled injection pen. It delivers tirzepatide under the skin once a week according to the prescribed treatment plan.
The 15 mg strength is one of the available dose strengths. It is generally reached through gradual dose escalation when prescribed by a healthcare professional. It is not intended to be a starting dose for someone new to treatment.
The pen is designed to deliver four fixed doses. Patients should read the official instructions and receive guidance from their doctor, pharmacist or nurse before using it
3. Uses and Approved Indications
Mounjaro may be prescribed for the following purposes, depending on the applicable authorisation and the patient's eligibility.
Type 2 Diabetes Management
Tirzepatide helps regulate blood glucose levels by acting on hormone receptors involved in glucose control. It may be prescribed alongside dietary changes, physical activity and other diabetes treatments when clinically appropriate.
Weight Management
Mounjaro may also be prescribed for weight management in eligible adults, alongside a reduced-calorie diet and increased physical activity. Eligibility depends on factors such as body mass index (BMI), weight-related health conditions and applicable prescribing guidance.
Important: Mounjaro is not suitable for everyone. A healthcare professional must determine whether treatment is appropriate.
4. Strength and Pack Details
Product feature
Details
Brand
Mounjaro
Active ingredient
Tirzepatide
Strength
15 mg per dose
Dosage form
Injectable solution
Device
KwikPen pre-filled pen
Administration
Subcutaneous injection
Frequency
Once weekly
Doses per pen
Four fixed doses
Manufacturer
Eli Lilly
Supply status in Ireland
Prescription-only
The pen must be used according to the package leaflet. Do not share the pen with another person, even if the needle has been changed.
Possible Side Effects
Like other prescription medicines, Mounjaro can cause side effects.
Commonly reported effects include:
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Abdominal discomfort
- Reduced appetite
Digestive side effects can be more noticeable when treatment begins or when the dose is increased.
Seek urgent medical attention if you experience symptoms of a serious allergic reaction or severe, persistent abdominal pain, particularly if it spreads to your back or is accompanied by vomiting.
Discuss any new or persistent symptoms with your doctor or pharmacist. The full list of possible side effects and precautions is provided in the official patient information leaflet.
Who Should Use Mounjaro 15 mg?
Mounjaro should be used only by people for whom it has been prescribed following an appropriate medical assessmuent.
Before treatment, tell your healthcare professional about:
- Your medical history
- Other medicines you take
- Any previous reactions to tirzepatide or related medicines
- Pregnancy, plans for pregnancy or breastfeeding
- Any history of pancreatitis or significant digestive problems
Do not start treatment, increase your dose or switch from another medicine without professional advice.
Storage and Handling
- Store the unopened pen according to the package leaflet, generally in a refrigerator at 2°C–8°C.
- Do not freeze the medicine.
- Protect it from excessive heat and light.
- Follow the official instructions for storage after first use.
- Keep it out of the reach of children.
- Do not use the pen if it has been frozen, damaged or stored incorrectly.